Dr Lal Pathlabs Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Dr Lal Pathlabs  (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq? X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights.

The NovaSeq? X system features Illumina's cutting-edge XLEAP-SBS? chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements.

?With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,? said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. ?This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.?

Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (?NGS?), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.

Powered by Capital Market - Live News

Dr Lal Pathlabs  (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq? X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights.

The NovaSeq? X system features Illumina's cutting-edge XLEAP-SBS? chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements.

?With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,? said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. ?This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.?

Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (?NGS?), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.

Powered by Capital Market - Live News

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 25 April 2025, inter alia, have recommended the final dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Dr. Lal PathLabs announced that the Annual General Meeting(AGM) of the company will be held on 28 June 2025.

Powered by Capital Market - Live News